Can Augmentin Be Given in Pregnancy for Sinus Infection?
Yes, Augmentin (amoxicillin-clavulanate) can be safely prescribed during pregnancy for sinus infections, as penicillins are the safest antibiotic class for treating acute rhinosinusitis in pregnant women.
Evidence-Based Recommendation
The 2016 Rhinology expert panel guidelines explicitly state that penicillin and cephalosporin are the safest antibiotic classes for treating acute rhinosinusitis during pregnancy and can be given when endoscopic evidence of purulence is present 1. Since Augmentin is a penicillin-based antibiotic, it falls squarely within this recommended category.
The FDA drug label confirms Augmentin is Pregnancy Category B, meaning reproduction studies in pregnant rats and mice at doses up to 1,200 mg/kg/day (4.9 and 2.8 times the maximum adult human dose) revealed no evidence of harm to the fetus 2. While there are no adequate well-controlled studies in pregnant women, the animal data is reassuring.
Clinical Algorithm for Use
When to prescribe:
- Acute bacterial sinusitis with purulent discharge
- Acute exacerbations of chronic rhinosinusitis
- Any trimester of pregnancy (including first trimester)
- Can be given immediately before delivery if clinically indicated
When to exercise additional caution:
- Women at risk of preterm delivery should ideally use amoxicillin alone rather than amoxicillin-clavulanate, as one 2001 study suggested a potential association with necrotizing enterocolitis in neonates when given prophylactically for premature rupture of membranes 2. However, a 2022 review concluded this risk was not confirmed in subsequent studies and that amoxicillin-clavulanate can be prescribed at any stage including just before delivery when clinically required 3.
Important Caveats and Pitfalls
The necrotizing enterocolitis concern: The FDA label mentions that prophylactic Augmentin in women with premature rupture of fetal membranes may be associated with increased risk of necrotizing enterocolitis in neonates 2. However, this was based on a single 2001 study in a specific prophylactic context (preterm prelabor rupture of membranes), not therapeutic use for active infection. The 2022 French review specifically addressed this concern and concluded the available data do not support an increased risk with therapeutic use in late pregnancy 3.
Key distinction: There is a critical difference between:
- Prophylactic use in asymptomatic women with premature rupture of membranes (where the concern arose)
- Therapeutic use for active sinus infection (your clinical scenario)
For therapeutic treatment of sinus infections, the benefits clearly outweigh theoretical risks at any stage of pregnancy.
Safety Profile
A population-based case-control study of 6,935 pregnant women with offspring having congenital abnormalities versus 10,238 controls found no increased risk of congenital abnormalities with Augmentin treatment during pregnancy (odds ratio 1.4,95% CI 0.9-2.0) 4. The study specifically examined treatment during the second-third months of pregnancy (the critical period for major congenital abnormalities) and found no association with any congenital abnormality group.
Antibiotics to Avoid in Pregnancy
The guidelines are clear about which antibiotics should NOT be used during pregnancy for sinus infections 1:
- Tetracyclines (including doxycycline)
- Aminoglycosides
- Trimethoprim-sulfamethoxazole
- Fluoroquinolones
Practical Prescribing
Standard dosing of Augmentin 875 mg/125 mg twice daily is appropriate for acute bacterial sinusitis in pregnancy, consistent with non-pregnant adult dosing. The recent 2026 JAMA study found no difference in treatment failure between amoxicillin-clavulanate versus amoxicillin alone for acute sinusitis in adults, though this was not pregnancy-specific 5. If you prefer to avoid clavulanate entirely (particularly in women at risk for preterm delivery), amoxicillin alone is an acceptable alternative.
Bottom line: Augmentin is safe and appropriate for treating sinus infections throughout pregnancy, prioritizing maternal health and fetal safety while effectively treating bacterial rhinosinusitis.